Related Experiment Videos
[Percutaneous pulmonary valvuloplasty. Short-term and long-term results]
M Ledesma Velasco1, J L Salgado Escobar, J Munayer Calderon
1Departamento de Hemodinámica y Fisiología Pulmonar del Hospital General del Centro Médico La Raza del Instituto Mexicano del Seguro Social.
Summary
Percutaneous pulmonary valvuloplasty effectively treats congenital pulmonary valve stenosis, significantly reducing pressure gradients and improving patient outcomes long-term. This minimally invasive procedure offers a safe and effective alternative for pediatric and adult patients.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pediatric Cardiology
Context:
- Congenital pulmonary valve stenosis is a significant cause of right ventricular outflow tract obstruction.
- Traditional surgical interventions carry substantial risks, particularly in pediatric populations.
- Percutaneous pulmonary valvuloplasty has emerged as a less invasive therapeutic option.
Purpose:
- To evaluate the efficacy and safety of percutaneous pulmonary valvuloplasty in patients with congenital pulmonary valve stenosis.
- To assess the short-term and long-term hemodynamic outcomes and clinical status following the procedure.
- To determine the durability of the intervention and identify potential complications.
Summary:
- Twenty patients with congenital pulmonary valve stenosis underwent percutaneous angioplasty, with ages ranging from 8 months to 32 years.
- Significant reductions in valvular gradient and right ventricle systolic pressure were observed immediately post-procedure and were sustained at 3 months and 1 year.
- Most patients experienced asymptomatic status, with improvements in electrocardiographic and echocardiographic findings, and a low rate of restenosis.
Impact:
- Percutaneous pulmonary valvuloplasty provides a highly effective and durable treatment for congenital pulmonary valve stenosis.
- The procedure demonstrates a favorable safety profile, with minimal complications and short hospital stays.
- Valvuloplasty is considered the treatment of choice for congenital pulmonary valve stenosis, offering significant clinical and hemodynamic benefits.